We are live on ! Find out more

iShares US Pharmaceuticals ETF

IHE

Market cap $1.6B

106.61 USD

+2.94

2.84%

At close Updated Oct 29, 4:00 PM EDT

1 day

2.84%

5 days

2.25%

1 month

4.25%

3 months

3%

6 months

25.69%

Year to date

25.62%

1 year

44.15%

5 years

69.98%

10 years

134.46%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40%

Neutral 20%

Negative 40%

From Laggard to Leader: The Surprising Comeback of Healthcare

Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.

From Laggard to Leader: The Surprising Comeback of Healthcare

The Motley Fool

Better Pharma ETF: iShares IHE vs. State Street XPH

The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S. Pharmaceuticals ETF provides a higher dividend yield of 1.4% compared to 0.4% for the State Street SPDR S&P Pharmaceuticals ETF.

Better Pharma ETF: iShares IHE vs. State Street XPH

Zacks Investment Research

Execution of Pharma Tariffs Brings These ETFs Into Focus

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

Execution of Pharma Tariffs Brings These ETFs Into Focus

Zacks Investment Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

IHE: Innovation Supports The Outlook, Valuation Limits Conviction

iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity therapies, robust drug pipelines, and demographic tailwinds but faces high concentration risk. Short-term catalysts include LLY's earnings momentum, FDA drug approvals, sector M&A activity, and potential interest rate improvements.

IHE: Innovation Supports The Outlook, Valuation Limits Conviction

IHE: Large-Cap Pharma Cools After A Hot Summer

I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings totaling 76%. Technical trends have turned concerning, with a recent breach of trendline support and a possible 10% correction to $97 likely through October.

IHE: Large-Cap Pharma Cools After A Hot Summer

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

The Motley Fool

XLV vs. IHE: Which Healthcare ETF Is the Better Buy?

The Health Care Select Sector SPDR Fund (XLV) carries a significantly lower expense ratio than the iShares U.S. Pharmaceuticals ETF (IHE). IHE concentrates exclusively on the pharmaceutical industry, while XLV spreads its bets across the broader healthcare sector.

XLV vs. IHE: Which Healthcare ETF Is the Better Buy?

Zacks Investment Research

Will Generic Drug Tariffs Impact Pharma ETFs?

New U.S. tariffs on generic drugs could pressure drugmakers and influence pharmaceutical ETFs. Here's what investors should watch.

Will Generic Drug Tariffs Impact Pharma ETFs?

Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide

Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge excluding Japan was little changed after swinging between gains and losses.

Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide

See News Rankings

Price charts implemented using Lightweight Charts™